(Q38081969)

28 August 2017

title

Hepatitis B core-based virus-like particles to present heterologous epitopes (English)

1 reference

28 August 2017

1 reference

4

Xavier Saelens

1 reference

28 August 2017

3

Bert Schepens

1 reference

28 August 2017

Kenny Roose

1

1 reference

28 August 2017

Sarah De Baets

series ordinal

2

1 reference

28 August 2017

publication date

1 February 2013

1 reference

Expert Review of Vaccines

28 August 2017

published in

1 reference

28 August 2017

volume

12

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

183-198

1 reference

Hepatitis B virus infection: epidemiology and vaccination

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A "NEW" ANTIGEN IN LEUKEMIA SERA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

An antigen detected in the blood during the incubation period of serum hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Human hepatitis B vaccine from recombinant yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

The preS1 antigen of hepatitis B virus is highly immunogenic at the T cell level in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

T- and B-cell recognition of hepatitis B viral antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Weak immunogenicity of the preS2 sequence and lack of circumventing effect on the unresponsiveness to the hepatitis B virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Hepatitis B virus capsid particles are assembled from core-protein dimer precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Native hepatitis B virions and capsids visualized by electron cryomicroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Hepatitis B precore protein: pathogenic potential and therapeutic promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Full-length hepatitis B virus core protein packages viral and heterologous RNA with similarly high levels of cooperativity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

The morphogenic linker peptide of HBV capsid protein forms a mobile array on the interior surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

The crystal structure of the human hepatitis B virus capsid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as well as for reverse transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Efficient Hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Role of p50/CDC37 in hepadnavirus assembly and replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A structural model for maturation of the hepatitis B virus core

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Production in B. subtilis of hepatitis B core antigen and of major antigen of foot and mouth disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Unusually high-level expression of a foreign gene (hepatitis B virus core antigen) in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Evaluation of Aspergillus niger as host for virus-like particle production, using the hepatitis B surface antigen as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Expression of cloned hepatitis B virus DNA in human cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A signal peptide encoded within the precore region of hepatitis B virus directs the secretion of a heterogeneous population of e antigens in Xenopus oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Co-expression of the hepatitis B surface and core antigens using baculovirus multiple expression vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

The role of envelope proteins in hepatitis B virus assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Application of a screening test for antibody the hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Universal influenza A vaccine: optimization of M2-based constructs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Hepatitis B virus capsid-like particles can display the complete, dimeric outer surface protein C and stimulate production of protective antibody responses against Borrelia burgdorferi infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A novel virus-like particle based on hepatitis B core antigen and substrate-binding domain of bacterial molecular chaperone DnaK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Role of B cells in antigen presentation of the hepatitis B core

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Interaction of the hepatitis B core antigen and the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Generation of chimeric HBc proteins with epitopes in E.coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Significant anti-tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8+ T cell/regulatory T cells in tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

The arginine-rich carboxy-terminal domain of the hepatitis B virus core protein mediates attachment of nucleocapsids to cell-surface-expressed heparan sulfate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Contamination of a recombinant hepatitis B virus nucleocapsid preparation with a human B-cell activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Advances and challenges in malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A malaria vaccine candidate based on a hepatitis B virus core platform

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Human T-cell recognition of the circumsporozoite protein of plasmodium falciparum: Immunodominant T-cell domains map to the polymorphic regions of the molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

From the circumsporozoite protein to the RTS, S/AS candidate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Protective immunity to pre-erythrocytic stage malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Influenza virus M2 protein has ion channel activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Influenza virus m2 ion channel protein is necessary for filamentous virion formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Influenza virus M2 protein mediates ESCRT-independent membrane scission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Interaction of Hsp40 with influenza virus M2 protein: implications for PKR signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Pandemic preparedness: toward a universal influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A universal influenza A vaccine based on the extracellular domain of the M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

M2e-based universal influenza A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Transient expression of the ectodomain of matrix protein 2 (M2e) of avian influenza A virus in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Versatile virus-like particle carrier for epitope based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Hepatitis B vaccines: protective efficacy and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Antibodies to synthetic peptides from the preS1 region of the hepatitis B virus (HBV) envelope (env) protein are virus-neutralizing and protective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Characterization of a hepatitis B and hepatitis delta virus receptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Hepatitis B virus infection and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Does antiviral therapy prevent hepatocellular carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Hepatitis B virus X gene and hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Epitope-specific regulation. II. A bistable, Igh-restricted regulatory mechanism central to immunologic memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Diversity of core antigen epitopes of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Comparative antigenicity and immunogenicity of hepadnavirus core proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Screen of multifunctional monoclonal antibodies against hepatitis B core virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Theileria annulata sporozoite antigen fused to hepatitis B core antigen used in a vaccination trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Immunogenicity of peptide fusions to hepatitis B virus core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis B virus core particles induces a strong and highly cross-reactive antibody response in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

Electron microscopy of hepatitis B core antigen synthesized in E. coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.12.150

21 January 2018

Identifiers

DOI

10.1586/ERV.12.150

1 reference

28 August 2017

1 reference